Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has identified GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Suzhou Puhe Biopharma Co. Ltd. has synthesized GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Tyligand Bioscience Ltd. has patented GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Kestrel Therapeutics Inc. has patented new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has described GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory and immunological disorders.

Betta Pharmaceuticals Co. Ltd. has identified GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, as well as autoimmune and inflammatory disorders.